PL353872A1 - Przeciwnowotworowe przeciwciała, białka i sposób zPrzeciwnowotworowe przeciwciała, białka i sposób zastosowania przeciwciał i białek przeciwnowotworowastosowania przeciwciał i białek przeciwnowotworowychych - Google Patents

Przeciwnowotworowe przeciwciała, białka i sposób zPrzeciwnowotworowe przeciwciała, białka i sposób zastosowania przeciwciał i białek przeciwnowotworowastosowania przeciwciał i białek przeciwnowotworowychych

Info

Publication number
PL353872A1
PL353872A1 PL00353872A PL35387200A PL353872A1 PL 353872 A1 PL353872 A1 PL 353872A1 PL 00353872 A PL00353872 A PL 00353872A PL 35387200 A PL35387200 A PL 35387200A PL 353872 A1 PL353872 A1 PL 353872A1
Authority
PL
Poland
Prior art keywords
proteins
antibodies
antitumor antibodies
expressed
disclosed
Prior art date
Application number
PL00353872A
Other languages
English (en)
Other versions
PL204822B1 (pl
Inventor
Kenneth L.Rock Kenneth L. Rock
DancellaFernandes Dancella Fernandes
Original Assignee
University Of Massachusettsuniversity Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusettsuniversity Of Massachusetts filed Critical University Of Massachusettsuniversity Of Massachusetts
Publication of PL353872A1 publication Critical patent/PL353872A1/pl
Publication of PL204822B1 publication Critical patent/PL204822B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL353872A 1999-07-23 2000-07-18 Izolowane przeciwciało, wiążące antygen fragmenty tego przeciwciała, linia komórkowa hybrydomy, kompozycja farmaceutyczna zawierająca izolowane przeciwciało, zastosowanie izolowanego przeciwciała, zestaw zawierający izolowane przeciwciało oraz środek ukierunkowany na komórki nowotworowe zawierający izolowane przeciwciało PL204822B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14533799P 1999-07-23 1999-07-23
PCT/US2000/019589 WO2001007481A1 (en) 1999-07-23 2000-07-18 Antitumor antibodies, proteins, and uses thereof

Publications (2)

Publication Number Publication Date
PL353872A1 true PL353872A1 (pl) 2003-12-01
PL204822B1 PL204822B1 (pl) 2010-02-26

Family

ID=22512634

Family Applications (1)

Application Number Title Priority Date Filing Date
PL353872A PL204822B1 (pl) 1999-07-23 2000-07-18 Izolowane przeciwciało, wiążące antygen fragmenty tego przeciwciała, linia komórkowa hybrydomy, kompozycja farmaceutyczna zawierająca izolowane przeciwciało, zastosowanie izolowanego przeciwciała, zestaw zawierający izolowane przeciwciało oraz środek ukierunkowany na komórki nowotworowe zawierający izolowane przeciwciało

Country Status (21)

Country Link
EP (1) EP1200476B1 (pl)
JP (2) JP4842476B2 (pl)
KR (1) KR20020034164A (pl)
CN (1) CN1390233A (pl)
AT (1) ATE432292T1 (pl)
AU (1) AU6221200A (pl)
BR (1) BR0012704A (pl)
CA (1) CA2380066C (pl)
CZ (1) CZ303771B6 (pl)
DE (1) DE60042273D1 (pl)
ES (1) ES2327894T3 (pl)
HU (1) HU229416B1 (pl)
IL (2) IL147810A0 (pl)
MX (1) MXPA02000846A (pl)
NO (1) NO329234B1 (pl)
NZ (2) NZ516771A (pl)
PL (1) PL204822B1 (pl)
PT (1) PT1200476E (pl)
RU (1) RU2002104713A (pl)
WO (1) WO2001007481A1 (pl)
ZA (1) ZA200200856B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
BR0012704A (pt) * 1999-07-23 2002-07-02 Univ Massachusetts Anticorpos antitumor, proteìnas e usos dos mesmos
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
DE10016025B4 (de) 2000-03-31 2005-06-16 Hde Solutions Gmbh Verfahren zur Herstellung von Hohlkörpern
WO2003049704A2 (en) * 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
CN1468956A (zh) * 2002-07-15 2004-01-21 杨 琴 高效表达治疗肿瘤的抗体的重组病毒及其用途
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267615A3 (en) * 1986-11-13 1989-05-03 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
US5104652A (en) * 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
BR0012704A (pt) * 1999-07-23 2002-07-02 Univ Massachusetts Anticorpos antitumor, proteìnas e usos dos mesmos

Also Published As

Publication number Publication date
ATE432292T1 (de) 2009-06-15
NO329234B1 (no) 2010-09-20
AU6221200A (en) 2001-02-13
HU229416B1 (en) 2013-12-30
NZ516771A (en) 2004-02-27
NO20020329L (no) 2002-02-25
EP1200476B1 (en) 2009-05-27
NO20020329D0 (no) 2002-01-22
KR20020034164A (ko) 2002-05-08
JP2003508525A (ja) 2003-03-04
JP4842476B2 (ja) 2011-12-21
EP1200476A4 (en) 2004-11-17
CA2380066A1 (en) 2001-02-01
WO2001007481A1 (en) 2001-02-01
IL187595A0 (en) 2008-03-20
CZ303771B6 (cs) 2013-05-02
PL204822B1 (pl) 2010-02-26
NZ530390A (en) 2005-09-30
RU2002104713A (ru) 2003-08-27
CA2380066C (en) 2011-07-05
HUP0202270A2 (en) 2002-10-28
IL147810A0 (en) 2002-08-14
WO2001007481A9 (en) 2002-08-29
CZ2002288A3 (cs) 2002-06-12
EP1200476A1 (en) 2002-05-02
CN1390233A (zh) 2003-01-08
ZA200200856B (en) 2003-07-30
DE60042273D1 (de) 2009-07-09
BR0012704A (pt) 2002-07-02
ES2327894T3 (es) 2009-11-05
JP2011219477A (ja) 2011-11-04
IL187595A (en) 2013-05-30
PT1200476E (pt) 2009-08-10
HUP0202270A3 (en) 2012-09-28
MXPA02000846A (es) 2002-10-23

Similar Documents

Publication Publication Date Title
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
MXPA02004666A (es) Gelatinas recombinantes.
WO2002019963A3 (en) Synthetic erythropoiesis stimulating proteins
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
BG104236A (en) Transgenous mammals producing oligosaccharides in their milk
GEP20105118B (en) Anti-vegf antibodies
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
ID23374A (id) Halogenopirimidin
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
DE69634077D1 (de) Haemophilus adhäsionsproteinen
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
BG101787A (en) Aprotinine options having improved properties
AU3711597A (en) A novel galanin receptor
AU2895797A (en) Carbohydrate derivatives and their solid-phase synthesis
SE9802507D0 (sv) Novel salts
WO1998023762A3 (en) Methods of producing a recombinant protein
GB2374871A (en) Peptide fragments of colostrinin and their use
WO1997010258A3 (de) Antikörper gegen an oberflächen von carcinom-zellen ausserhalb von desmosomen exponierte epitope desmosomaler cadherine
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
ATE231887T1 (de) Protein mit anti-tumorwirkung

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20140718